MAMSCAN · New Method for Early Stage Breast Cancer Detection

Imaqen Oy is a Finnish healthcare technology company developing an imaging solution for the early detection of breast cancer. Since 2016, we have worked on our proprietary technology, Amiqo that has the same diagnostic accuracy as the key competitors, mammography and breast ultrasound, while it is non-invasive and non-radiating. Amiqo consists of an imaging device using a patented μm-wavelength scanning, a proprietary frequency analysis enhanced by AI and an anatomic map pointing out the suspect areas for diagnosis carried out by a specialist doctor. Our initial target customers are private health care clinics who already have gynecological services. They are under pressure of finding affordable solutions for preventive healthcare fueled by women’s increasing awareness of the importance of early detection. The economic effect is considerable: the operating costs are significantly lower, it enables more images taken/day and its acquisition cost is neutral or lower. The end-clients are women under 50 or over 70 who fall outside the population level mammography screenings. 50% of breast cancer cases are found in these age groups annually. For women, Amiqo examination will be less than half the price of any current alternative. Through lower mortality and decreased treatment costs, Amiqo has a direct impact at societal level as breast cancer is the most common, the deadliest and the most expensive cancer for women in Europe. The next steps involve extensive clinical testing to finalise the product design, acquire certification and attain clinical acceptance. The SMEI funding will speed up the business planning in our priority markets, Finland, Sweden, France, the UK and Spain, including IPR pipeline, clinical acceptance strategy, user and technical requirements. The commercialization stage will be achieved by €1,76 million with the launch foreseen in 2020. The first goal is a 30% market share of the non-invasive imaging market by 2026 resulting in sales of €82 million.